A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-ALIVE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 16 Jul 2017 Brazil and Romania were planned locations for the trial, but in actuality, no subjects from either country were screened or randomized. (Confirmed from investigator- Atul Deodhar, Reply received on July 16, 2017, deodhara@ohsu.edu)
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of data through week 28, presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top